AR080368A1 - Disoluciones acuosas transparentes de acetonido de fluocinolona para el tratamiento de la inflamacion de oido - Google Patents
Disoluciones acuosas transparentes de acetonido de fluocinolona para el tratamiento de la inflamacion de oidoInfo
- Publication number
- AR080368A1 AR080368A1 ARP110100633A ARP110100633A AR080368A1 AR 080368 A1 AR080368 A1 AR 080368A1 AR P110100633 A ARP110100633 A AR P110100633A AR P110100633 A ARP110100633 A AR P110100633A AR 080368 A1 AR080368 A1 AR 080368A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- composition according
- fluocinolone acetonide
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composicion farmacéutica otica estéril sin conservantes en forma de una disolucion acuosa transparente que comprende un 0,01-0,10% (p/v) de acetonido de fluocinolona, opcionalmente acompanado por un 0,1-0,8% de ciprofloxacina o una sal farmacéuticamente aceptable de la misma, un tensioactivo ionico, un agente de ajuste de la tonicidad y un agente de aumento de la viscosidad. Es util la prevencion y/o el tratamiento de la inflamacion de oído, opcionalmente acompanada por infeccion bacteriana, y para la administracion desde recipientes de un solo uso. Reivindicacion 1: Composicion farmacéutica otica estéril sin conservantes en forma de una disolucion acuosa transparente que comprende los siguientes componentes, en porcentajes en p/v: (i) un 0,01-0,10% de Acetonido de Fluocinolona, opcionalmente acompanado por un 0,1-0,8% de Ciprofloxacina o una sal farmacéuticamente aceptable de la misma; ii) un total del 0,5-4,0% de uno o más tensioactivos no ionicos farmacéuticamente aceptables con un valor de equilibrio hidrofilo-lipofilo (HLB) entre 14 y 18; (iii) un total del 0,5-4,0% de uno o más agentes de ajuste de la tonicidad farmacéuticamente aceptables; (iv) un total del 0,05-1,00% de uno o más agentes de aumento de la viscosidad farmacéuticamente aceptables; (v) opcionalmente, una cantidad de uno o más agentes de ajuste del pH farmacéuticamente aceptables en c.s. para ajustar el pH a 4,0-5,0; y vi) agua. Reivindicacion 3: Composicion farmacéutica segun la reivindicacion 2, en la que el tensioactivo no ionico farmacéuticamente aceptable es Polisorbato 80. Reivindicacion 5: Composicion farmacéutica segun la reivindicacion 4, en la que el agente de ajuste de la tonicidad farmacéuticamente aceptable es glicerina. Reivindicacion 8: Composicion farmacéutica segun la reivindicacion 7, en la que el agente de aumento de la viscosidad farmacéuticamente aceptable es Povidona K 90F. Reivindicacion 10: Composicion farmacéutica segun la reivindicacion 1, en la que los porcentajes en p/v son los siguientes: (i) un 0,02-0,03% de Acetonido de Fluocinolona, opcionalmente acompanado por un 0,2-0,4% de Ciprofloxacina o una sal farmacéuticamente aceptable de la misma; (ii) un 2-3% de Polisorbato 80; (iii) un 2-3% de glicerina; (iv) un 0,1-0,3% de Povidona K 90F; (v) opcionalmente, una cantidad de uno o más agente de ajuste del pH farmacéuticamente aceptables en c.s. para ajustar el pH a 4,0-5,0; y (vi) agua. Reivindicacion 11: Composicion farmacéutica segun cualquiera de las reivindicaciones 1 a 10, en la que la composicion farmacéutica se esteriliza y está contenida en recipientes de dosis unica desechable para uso topico en forma de gotas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10155005A EP2366408B1 (en) | 2010-03-01 | 2010-03-01 | Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080368A1 true AR080368A1 (es) | 2012-04-04 |
Family
ID=42668238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100633A AR080368A1 (es) | 2010-03-01 | 2011-03-01 | Disoluciones acuosas transparentes de acetonido de fluocinolona para el tratamiento de la inflamacion de oido |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8932610B2 (es) |
| EP (1) | EP2366408B1 (es) |
| JP (1) | JP5744922B2 (es) |
| KR (1) | KR101777157B1 (es) |
| CN (1) | CN102811741B (es) |
| AR (1) | AR080368A1 (es) |
| AU (1) | AU2011223095B2 (es) |
| BR (1) | BR112012021638B1 (es) |
| CA (1) | CA2790652C (es) |
| DK (1) | DK2366408T3 (es) |
| ES (1) | ES2391721T3 (es) |
| MX (1) | MX2012010009A (es) |
| PL (1) | PL2366408T3 (es) |
| RU (1) | RU2549465C2 (es) |
| WO (1) | WO2011107436A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2604413C1 (ru) * | 2015-06-17 | 2016-12-10 | Марина Николаевна Вольгова | Способ лечения хронического аллергического наружного отита |
| JP2017008047A (ja) * | 2015-06-25 | 2017-01-12 | 参天製薬株式会社 | 注射剤 |
| JP6255134B1 (ja) * | 2016-11-02 | 2017-12-27 | ヴェローチェ・バイオファーマ・エルエルシー | 耳炎の治療のための組成物および方法 |
| KR102075694B1 (ko) | 2017-12-18 | 2020-02-10 | 경희대학교 산학협력단 | 시지지움 큐미니 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 조성물 |
| KR102094228B1 (ko) | 2017-12-18 | 2020-03-27 | 경희대학교 산학협력단 | 운카리아 린초필라 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 조성물 |
| KR102007096B1 (ko) | 2017-12-18 | 2019-08-02 | 경희대학교 산학협력단 | 비스쿰 오발리포리움 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 조성물 |
| KR102035845B1 (ko) | 2018-05-31 | 2019-10-23 | 경희대학교 산학협력단 | 난청의 예방 또는 치료용 조성물 |
| KR102030123B1 (ko) | 2018-05-31 | 2019-10-08 | 경희대학교 산학협력단 | 난청의 예방 또는 치료용 조성물 |
| KR102131044B1 (ko) | 2018-05-31 | 2020-07-08 | 경희대학교 산학협력단 | 난청의 예방 또는 치료용 조성물 |
| CN109260152A (zh) * | 2018-11-13 | 2019-01-25 | 禹州市中医院 | 一种盐酸洛美沙星滴耳液 |
| CN112022805A (zh) * | 2020-10-20 | 2020-12-04 | 内蒙古盛唐国际蒙医药研究院有限公司 | 一种高稳定性复方醋酸氟轻松酊及其制备方法 |
| KR20220091176A (ko) | 2020-12-23 | 2022-06-30 | (주)인비보텍 | 난청의 예방 또는 치료용 조성물 |
| KR20220091177A (ko) | 2020-12-23 | 2022-06-30 | (주)인비보텍 | 난청의 예방 또는 치료용 조성물 |
| US11672798B2 (en) * | 2021-06-03 | 2023-06-13 | Laboratorios Salvat, S.A. | Ciprofloxacin ophthalmic topical composition for treating ocular disease |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1013180A (en) * | 1962-10-30 | 1965-12-15 | Ici Ltd | Steroid compositions |
| US3326808A (en) * | 1965-08-25 | 1967-06-20 | Pfizer & Co C | Antiseptic detergent composition |
| GB1133800A (en) * | 1966-11-10 | 1968-11-20 | Ici Ltd | Pharmaceutical compositions |
| GB1411432A (en) * | 1972-01-10 | 1975-10-22 | Medisan Ab | Skin treating compositions |
| US4013792A (en) * | 1974-04-11 | 1977-03-22 | Warner-Lambert Company | Process for the production of base for topical steroids |
| AU7776275A (en) | 1974-04-11 | 1976-08-05 | Warner Lambert Co | Production of base for topical steroids |
| US3934013A (en) | 1975-02-21 | 1976-01-20 | Syntex (U.S.A.) Inc. | Pharmaceutical composition |
| DE3704907A1 (de) | 1987-02-17 | 1988-08-25 | Bayer Ag | Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden |
| AU4201189A (en) | 1988-08-26 | 1990-03-23 | Alcon Laboratories, Inc. | Combination of quinolone antibiotics and steroids for topical ophthalmic use |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| ZA964653B (en) | 1995-06-06 | 1996-12-12 | Bayer Ag | Non-irritation non-sensitizing non-ototoxic otic anti-bacterial compositions |
| ES2106680B1 (es) | 1995-08-03 | 1998-07-01 | Vita Invest Sa | Composiciones acuosas conteniendo ciprofloxacino y utilizacion y procedimiento correspondientes. |
| CA2289618A1 (en) * | 1997-05-14 | 1998-11-19 | Shin-Ichi Yasueda | Aqueous suspension preparations with excellent redispersibility |
| US5997518A (en) * | 1998-01-14 | 1999-12-07 | Laibovitz; Robert A. | Apparatus and method for delivery of small volumes of liquid |
| US5990100A (en) * | 1998-03-24 | 1999-11-23 | Panda Pharmaceuticals, L.L.C. | Composition and method for treatment of psoriasis |
| AU3843999A (en) | 1998-05-07 | 1999-11-23 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
| US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US6235722B1 (en) * | 1999-09-24 | 2001-05-22 | Balakrishnan Jayapathy | Pharmacological preparation |
| EP1214056B1 (en) | 1999-09-24 | 2003-10-29 | Alcon Inc. | Topical suspension formulations containing ciprofloxacin and dexamethasone |
| US20010049366A1 (en) * | 2000-02-09 | 2001-12-06 | Alcon Universal Ltd. | Topical solution formulations containing an antibiotic and a corticosteroid |
| AU2001278779A1 (en) * | 2000-08-25 | 2002-03-04 | Senju Pharmaceutical Co. Ltd. | Aqueous suspension preparations |
| EP1321144B1 (en) * | 2000-09-13 | 2010-12-08 | Santen Pharmaceutical Co., Ltd. | Eye drops |
| WO2004052236A2 (en) * | 2002-12-06 | 2004-06-24 | Arriva Pharmaceuticals, Inc. | Methods and compositions for treatment of otitis media |
| CN1829510A (zh) * | 2003-07-31 | 2006-09-06 | 法马西亚和厄普乔恩公司 | 抗炎剂的可分散性制剂 |
| DE10347994A1 (de) * | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| GB0413954D0 (en) * | 2004-06-22 | 2004-07-28 | Altunkaya Ali | Compositions for topical treatment |
| US20090111780A1 (en) | 2007-10-31 | 2009-04-30 | Everett Laboratories, Inc. | Compositions and methods for treatment of ear canal infection and inflammation |
| WO2010011466A2 (en) * | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
| US8318817B2 (en) * | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
-
2010
- 2010-03-01 EP EP10155005A patent/EP2366408B1/en active Active
- 2010-03-01 ES ES10155005T patent/ES2391721T3/es active Active
- 2010-03-01 PL PL10155005T patent/PL2366408T3/pl unknown
- 2010-03-01 DK DK10155005.1T patent/DK2366408T3/da active
- 2010-03-24 US US12/730,681 patent/US8932610B2/en active Active
-
2011
- 2011-02-28 AU AU2011223095A patent/AU2011223095B2/en active Active
- 2011-02-28 CN CN201180009966.6A patent/CN102811741B/zh active Active
- 2011-02-28 KR KR1020127025195A patent/KR101777157B1/ko active Active
- 2011-02-28 RU RU2012141641/15A patent/RU2549465C2/ru active
- 2011-02-28 CA CA2790652A patent/CA2790652C/en active Active
- 2011-02-28 JP JP2012555383A patent/JP5744922B2/ja active Active
- 2011-02-28 WO PCT/EP2011/052939 patent/WO2011107436A2/en not_active Ceased
- 2011-02-28 BR BR112012021638-4A patent/BR112012021638B1/pt active IP Right Grant
- 2011-02-28 MX MX2012010009A patent/MX2012010009A/es active IP Right Grant
- 2011-03-01 AR ARP110100633A patent/AR080368A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2391721T3 (es) | 2012-11-29 |
| EP2366408A1 (en) | 2011-09-21 |
| DK2366408T3 (da) | 2012-10-22 |
| CA2790652A1 (en) | 2011-09-09 |
| EP2366408B1 (en) | 2012-07-18 |
| WO2011107436A3 (en) | 2011-11-10 |
| US20110212932A1 (en) | 2011-09-01 |
| AU2011223095B2 (en) | 2015-09-17 |
| PL2366408T3 (pl) | 2013-01-31 |
| CA2790652C (en) | 2016-11-08 |
| MX2012010009A (es) | 2012-09-28 |
| JP5744922B2 (ja) | 2015-07-08 |
| AU2011223095A1 (en) | 2012-08-16 |
| BR112012021638A2 (pt) | 2017-08-08 |
| RU2549465C2 (ru) | 2015-04-27 |
| CN102811741B (zh) | 2015-05-13 |
| KR20130026430A (ko) | 2013-03-13 |
| WO2011107436A2 (en) | 2011-09-09 |
| KR101777157B1 (ko) | 2017-09-26 |
| BR112012021638B1 (pt) | 2020-10-27 |
| RU2012141641A (ru) | 2014-04-10 |
| JP2013521245A (ja) | 2013-06-10 |
| US8932610B2 (en) | 2015-01-13 |
| HK1162145A1 (en) | 2012-08-24 |
| CN102811741A (zh) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080368A1 (es) | Disoluciones acuosas transparentes de acetonido de fluocinolona para el tratamiento de la inflamacion de oido | |
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| AR113034A2 (es) | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado | |
| AR088383A1 (es) | Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles | |
| EA201492021A1 (ru) | Антительный состав | |
| PE20151425A1 (es) | Formulaciones farmaceuticas muy concentradas que comprenden un anticuerpo anti-cd20 | |
| PE20160526A1 (es) | Composiciones oftalmologicas no irritantes de povidona-yodo | |
| CL2013003016A1 (es) | Una composicion oftalmica topica para el tratamiento y/o la profilaxis de una infeccion producida por un microorganismo o un trastorno de al menos un tejido ocular, que comprende a) 0,01 a 10% de povidona yodada y b) un esteroide seleccionado de acetato de prednisolona, etabonato de loteprednol, difluprednato, entre otros, o bromfenaco. | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| US11154578B2 (en) | Compositions and methods of use | |
| AR091902A1 (es) | Formulacion liquida de un conjugado de insulina de accion prolongada | |
| AR106776A1 (es) | Composiciones de cuidado oral | |
| MX2013006816A (es) | Formulaciones farmaceuticas de azol para la administracion parenteral y metodos para preparar y usar las mismas como tratamiento de las enfermedades sensibles a los compuestos de azol. | |
| ECSP12011967A (es) | Métodos y composiciones para el tratamiento rápido de otitis externa | |
| CO7230346A2 (es) | Uso de agente quelante y compuestos antimicrobianos de pétido | |
| AR045070A1 (es) | Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico | |
| AR055591A1 (es) | Una composicion topica protectora de la piel y su uso | |
| AR086672A1 (es) | Formulaciones de furina recombinante | |
| ES2640289T3 (es) | Combinaciones con un péptido de esqueleto ciclado | |
| AR077458A1 (es) | Composiciones de copolimero en bloque de oxido de etileno oxido de butileno | |
| JP2009161456A (ja) | 眼科用組成物 | |
| CL2008001536A1 (es) | Composicion farmaceutica compuesta por la combinacion sinergica de un agente antimicrobiano como ciprofloxacino y un agente antioxidante como acido ascorbico, la concentracion de ciprofloxacino va desde 250 mg hasta 1 gr y desde 50 mg hasta 200 mg para acido ascorbico, en una unidad de dosis; y uso en infecciones urinarias. | |
| CL2009002197A1 (es) | Composicion farmaceutica oftalmica topica que comprende tandospirona y una sal tampon; util en el tratamiento de la atrofia geografica del ojo. | |
| CA3219596A1 (en) | Compositions and uses therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |